Skip to main content
MedPathMedPath Home
Clinical Trials/EUCTR2005-001086-34-IT
EUCTR2005-001086-34-IT
Active, not recruiting
Not Applicable

A randomised Phase III trial of 6 months versus 12 months withdrawal of methotrexate in patients with juvenile idiopathic arthritis in clinical remission

ISTITUTO GIANNINA GASLINI0 sitesJuly 1, 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsjuvenile idiopathic arthritisMedDRA version: 6.1Level: PTClassification code 10059177

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
juvenile idiopathic arthritis
Sponsor
ISTITUTO GIANNINA GASLINI
Status
Active, not recruiting
Last Updated
14 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 1, 2005
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Are the trial subjects under 18? yes
  • •Number of subjects for this age range:
  • •F.1\.2 Adults (18\-64 years) no
  • •F.1\.2\.1 Number of subjects for this age range
  • •F.1\.3 Elderly (\>\=65 years) no
  • •F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
The effect of duration of treatment with valganciclovir in children with renal transplantatioCondition 1: renal failure. Condition 2: CMV infection.Acute renal failureOther and unspecified infectious diseases
IRCT2015021321062N1Iran University of Medical Sciences86
Completed
Not Applicable
A randomised trial of 6 months versus 12 months withdrawal of methotrexate in patients with Juvenile Idiopathic Arthritis (JIA) in clinical remissioJuvenila Idiopathic Arthritis (JIA)Musculoskeletal DiseasesJuvenila idiopathic arthritis
ISRCTN18186313Pediatric Rheumatology International Trials Organisation (PRINTO) (Italy) and Wyeth Pharma300
Active, not recruiting
Not Applicable
A randomised trial of 6 months versus 12 months withdrawal of methotrexate in patiebts with juvenile idiopathic arthritis in clinical remission.Ensayo aleatorizado de retirada de Metotrexate a los 6 meses versus a los 12 meses, en pacientes con Artritis Idiopática Juvenil (AIJ) en remisión clínica - MTX withdrawal studyThe present study was designed for the follow up of two groups of patients with JIA, in whom remission was achieved using MTX. In group 1 treatment with MTX will be discontinued as early as 6 months after documentation of remission on medication. In group 2 treatment with MTX will be discontinued later than 12 mpnths after documentation of remission on medication.
EUCTR2005-001086-34-ESIstituto Giannina Gaslini-PRINTO200
Active, not recruiting
Not Applicable
A randomised trial of 6 months versus 12 months withdrawal of methotrexate in patients with juvenile idiopathic arthritis in clincal remission - MTX withdrawal studyThe present study was designed for the follow up of two groups of patients with JIA, in whom remission was achieved using MTX. In group 1 treatment with MTX will be discontinued as early as 6 months after documentation of remission on medication. In group 2 treatment with MTX will be discontinued later than 12 months after documentation of remission on medication
EUCTR2005-001086-34-DKISTITUTO GIANNINA GASLINI-PRINTO200
Active, not recruiting
Phase 1
3 or 6 cycles of platinum-based chemotherapy prior to maintenance avelumab for bladder cancernresectable locally advanced or metastatic urothelial carcinomaMedDRA version: 20.0Level: LLTClassification code 10046714Term: Urothelial carcinoma bladderSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2021-001975-17-ESQueen Mary University of London224